(CATX) Perspective Therapeutics - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE MKT (USA) | Market Cap: 464m USD | Total Return: 145% in 12m

Cancer Therapies, Drug Development, Clinical Trials
Total Rating 51
Safety 76
Buy Signal -0.59
Medical Devices
Industry Rotation: -5.6
Market Cap: 464M
Avg Turnover: 5.93M USD
ATR: 8.96%
Peers RS (IBD): 96.0
Risk 5d forecast
Volatility99.9%
Rel. Tail Risk-10.1%
Reward TTM
Sharpe Ratio1.14
Alpha110.52
Character TTM
Beta0.731
Beta Downside0.420
Drawdowns 3y
Max DD90.71%
CAGR/Max DD-0.13
EPS (Earnings per Share) EPS (Earnings per Share) of CATX over the last years for every Quarter: "2021-03": -0.01, "2021-06": -0.01, "2021-09": -0.02, "2021-12": -0.01, "2022-03": -0.01, "2022-06": -0.01, "2022-09": -0.03, "2022-12": -0.02, "2023-03": -0.01, "2023-06": -0.04, "2023-09": -0.04, "2023-12": -0.09, "2024-03": -0.02, "2024-06": -0.18, "2024-09": -0.21, "2024-12": -0.57, "2025-03": -0.25, "2025-06": -0.29, "2025-09": -0.35, "2025-12": -0.5058, "2026-03": 0,
EPS CAGR: 0.47%
EPS Trend: -64.3%
Last SUE: 3.15
Qual. Beats: 1
Revenue Revenue of CATX over the last years for every Quarter: 2021-03: 2.384, 2021-06: 2.359, 2021-09: 2.6, 2021-12: 2.71, 2022-03: 2.91, 2022-06: 2.505, 2022-09: 1.717, 2022-12: 1.835, 2023-03: 1.83, 2023-06: 1.5, 2023-09: 1.909, 2023-12: 0.337, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0.342, 2025-06: 0.29, 2025-09: 0.209, 2025-12: 0, 2026-03: null,
Rev. CAGR: -69.58%
Rev. Trend: -87.0%
Last SUE: -1.26
Qual. Beats: 0
Warnings

Interest Coverage Ratio -175.1 is critical

Altman Z'' -8.46 < 1.0 - financial distress zone

volatile

Tailwinds

No distinct edge detected

Description: CATX Perspective Therapeutics

Perspective Therapeutics, Inc. (CATX) develops targeted alpha therapies (TAT) for cancer treatment. This approach utilizes alpha-emitting radioisotopes for precise tumor cell destruction, a growing area in oncology.

Their pipeline includes VMT-a-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, both in Phase 1/2a clinical trials. The companys business model centers on the discovery and development of novel radiopharmaceutical drugs, a capital-intensive and high-risk sector due to extensive regulatory approval processes.

CATX also has a collaboration with Bristol Myers Squibb to evaluate a combination therapy for melanoma.

Further research on ValueRay can provide more in-depth analysis of CATXs clinical trial progress and market positioning within the radiopharmaceutical industry.

Headlines to Watch Out For
  • Clinical trial results for VMT-a-NET impact future revenue.
  • Regulatory approval for new therapies drives market access.
  • Collaboration agreements with large pharmaceutical companies provide funding.
  • Research and development expenses affect profitability.
  • Competition from existing cancer treatments limits market share.
Piotroski VR‑10 (Strict) 0.0
Net Income: -103.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.29 > 0.02 and ΔFCF/TA -7.28 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.28 > 3% & CFO -74.5m > Net Income -103.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.17 > 1.5 & < 3
Outstanding Shares: last quarter (73.8m) vs 12m ago 4.51% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.28% > 50% (prev 0.0%; Δ 0.28% > 0%)
Interest Coverage Ratio: -175.1 > 6 (EBITDA TTM -62.0m / Interest Expense TTM 376k)
Altman Z'' -8.46
A: 0.45 (Total Current Assets 148.4m - Total Current Liabilities 28.7m) / Total Assets 267.0m
B: -1.25 (Retained Earnings -334.8m / Total Assets 267.0m)
C: -0.22 (EBIT TTM -65.8m / Avg Total Assets 304.0m)
D: -5.58 (Book Value of Equity -334.7m / Total Liabilities 59.9m)
Altman-Z'' Score: -8.46 = D
Beneish M
DSRI: none (Receivables 6.00k/1.48m, Revenue 841k/0.0)
GMI: 1.00 (fallback, negative margins)
AQI: 1.03 (AQ_t 0.15 / AQ_t-1 0.15)
SGI: none (Revenue 841k / 0.0)
TATA: -0.11 (NI -103.1m - CFO -74.5m) / TA 267.0m)
Beneish M-Score: cannot calculate (missing components)
What is the price of CATX shares? As of April 06, 2026, the stock is trading at USD 4.41 with a total of 1,053,700 shares traded.
Over the past week, the price has changed by +15.14%, over one month by -13.53%, over three months by +61.54% and over the past year by +145.00%.
Is CATX a buy, sell or hold? Perspective Therapeutics has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CATX.
  • StrongBuy: 10
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CATX price?
Analysts Target Price 13 194.8%
Perspective Therapeutics (CATX) - Fundamental Data Overview as of 31 March 2026
P/E Forward = 25.7069
P/S = 524.5578
P/B = 2.4489
Revenue TTM = 841k USD
EBIT TTM = -65.8m USD
EBITDA TTM = -62.0m USD
Long Term Debt = 1.57m USD (from longTermDebt, last quarter)
Short Term Debt = 623k USD (from shortTermDebt, last quarter)
Debt = 1.63m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -29.0m USD (from netDebt column, last quarter)
Enterprise Value = 320.6m USD (463.7m + Debt 1.63m - CCE 144.7m)
Interest Coverage Ratio = -175.1 (Ebit TTM -65.8m / Interest Expense TTM 376k)
EV/FCF = -4.20x (Enterprise Value 320.6m / FCF TTM -76.3m)
FCF Yield = -23.81% (FCF TTM -76.3m / Enterprise Value 320.6m)
 FCF Margin = -9.08k% (FCF TTM -76.3m / Revenue TTM 841k)
 Net Margin = -12.3k% (Net Income TTM -103.1m / Revenue TTM 841k)
 Gross Margin = -166.3% ((Revenue TTM 841k - Cost of Revenue TTM 2.24m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.20 (Enterprise Value 320.6m / Total Assets 267.0m)
Interest Expense / Debt = 3.93% (Interest Expense 64.0k / Debt 1.63m)
Taxrate = 21.0% (US default 21%)
NOPAT = -52.0m (EBIT -65.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.17 (Total Current Assets 148.4m / Total Current Liabilities 28.7m)
Debt / Equity = 0.01 (Debt 1.63m / totalStockholderEquity, last quarter 207.0m)
 Debt / EBITDA = 0.47 (negative EBITDA) (Net Debt -29.0m / EBITDA -62.0m)
 Debt / FCF = 0.38 (negative FCF - burning cash) (Net Debt -29.0m / FCF TTM -76.3m)
 Total Stockholder Equity = 249.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.92% (Net Income -103.1m / Total Assets 267.0m)
RoE = -41.27% (Net Income TTM -103.1m / Total Stockholder Equity 249.9m)
RoCE = -26.18% (EBIT -65.8m / Capital Employed (Equity 249.9m + L.T.Debt 1.57m))
 RoIC = -20.68% (negative operating profit) (NOPAT -52.0m / Invested Capital 251.5m)
 WACC = 8.53% (E(463.7m)/V(465.3m) * Re(8.55%) + D(1.63m)/V(465.3m) * Rd(3.93%) * (1-Tc(0.21)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.95%
 [DCF] Fair Price = unknown (Cash Flow -76.3m)
 EPS Correlation: -64.26 | EPS CAGR: 0.47% | SUE: 3.15 | # QB: 1
Revenue Correlation: -87.00 | Revenue CAGR: -69.58% | SUE: -1.26 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.27 | Chg7d=+0.065 | Chg30d=+0.065 | Revisions Net=+2 | Analysts=8
EPS current Year (2026-12-31): EPS=-1.19 | Chg7d=+0.102 | Chg30d=+0.102 | Revisions Net=+0 | Growth EPS=+15.4% | Growth Revenue=-37.5%
EPS next Year (2027-12-31): EPS=-1.17 | Chg7d=-0.072 | Chg30d=-0.046 | Revisions Net=+0 | Growth EPS=+1.2% | Growth Revenue=-12.8%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle